Literature DB >> 22804479

Expert review on poliovirus immunity and transmission.

Radboud J Duintjer Tebbens1, Mark A Pallansch, Konstantin M Chumakov, Neal A Halsey, Tapani Hovi, Philip D Minor, John F Modlin, Peter A Patriarca, Roland W Sutter, Peter F Wright, Steven G F Wassilak, Stephen L Cochi, Jong-Hoon Kim, Kimberly M Thompson.   

Abstract

Successfully managing risks to achieve wild polioviruses (WPVs) eradication and address the complexities of oral poliovirus vaccine (OPV) cessation to stop all cases of paralytic poliomyelitis depends strongly on our collective understanding of poliovirus immunity and transmission. With increased shifting from OPV to inactivated poliovirus vaccine (IPV), numerous risk management choices motivate the need to understand the tradeoffs and uncertainties and to develop models to help inform decisions. The U.S. Centers for Disease Control and Prevention hosted a meeting of international experts in April 2010 to review the available literature relevant to poliovirus immunity and transmission. This expert review evaluates 66 OPV challenge studies and other evidence to support the development of quantitative models of poliovirus transmission and potential outbreaks. This review focuses on characterization of immunity as a function of exposure history in terms of susceptibility to excretion, duration of excretion, and concentration of excreted virus. We also discuss the evidence of waning of host immunity to poliovirus transmission, the relationship between the concentration of poliovirus excreted and infectiousness, the importance of different transmission routes, and the differences in transmissibility between OPV and WPV. We discuss the limitations of the available evidence for use in polio risk models, and conclude that despite the relatively large number of studies on immunity, very limited data exist to directly support quantification of model inputs related to transmission. Given the limitations in the evidence, we identify the need for expert input to derive quantitative model inputs from the existing data.
© 2012 Society for Risk Analysis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22804479     DOI: 10.1111/j.1539-6924.2012.01864.x

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  53 in total

1.  Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Stephen L Cochi; Derek T Ehrhardt; Noha H Farag; Stephen C Hadler; Lee M Hampton; Maureen Martinez; Steve G F Wassilak; Kimberly M Thompson
Journal:  Risk Anal       Date:  2018-01-03       Impact factor: 4.000

2.  Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  Risk Anal       Date:  2018-09-21       Impact factor: 4.000

3.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

4.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

Review 5.  Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Konstantin M Chumakov; Neal A Halsey; Tapani Hovi; Philip D Minor; John F Modlin; Peter A Patriarca; Roland W Sutter; Peter F Wright; Steven G F Wassilak; Stephen L Cochi; Jong-Hoon Kim; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

6.  Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination.

Authors:  Kasper H Kisjes; Radboud J Duintjer Tebbens; Gregory S Wallace; Mark A Pallansch; Stephen L Cochi; Steven G F Wassilak; Kimberly M Thompson
Journal:  J Infect Dis       Date:  2014-11-01       Impact factor: 5.226

7.  A mucosal adjuvant for the inactivated poliovirus vaccine.

Authors:  Benjamin P Steil; Patricia Jorquera; Janny Westdijk; Wilfried A M Bakker; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2013-12-13       Impact factor: 3.641

8.  Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.

Authors:  Radboud J Duintjer Tebbens; Lee M Hampton; Steven G F Wassilak; Mark A Pallansch; Stephen L Cochi; Kimberly M Thompson
Journal:  J Vaccines Vaccin       Date:  2016-10-03

9.  Phylogenetic patterns of human coxsackievirus B5 arise from population dynamics between two genogroups and reveal evolutionary factors of molecular adaptation and transmission.

Authors:  Cécile Henquell; Audrey Mirand; Jan Richter; Isabelle Schuffenecker; Blenda Böttiger; Sabine Diedrich; Elena Terletskaia-Ladwig; Christina Christodoulou; Hélène Peigue-Lafeuille; Jean-Luc Bailly
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

10.  Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.

Authors:  Kimberly M Thompson; Dominika A Kalkowska; Radboud J Duintjer Tebbens
Journal:  Vaccine       Date:  2015-02-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.